Literature DB >> 21248945

Neuroleptic malignant syndrome: a review.

R A O'Brien, G B Young.   

Abstract

There has recently been interest in neuroleptic malignant syndrome (NMS) as the disorder has been better characterized. Nms is still poorly recognized, however, by most physicians. Hyperpyrexia, rigidity, altered consciousness, autonomic instability, and enzymatic evidence of muscle breakdown after drug intake are the cardinal features. The authors of this article review the proposed pathogenesis, complications, and treatment of NMS.

Entities:  

Year:  1989        PMID: 21248945      PMCID: PMC2280345     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  47 in total

1.  Apparent neuroleptic malignant syndrome with clozapine and lithium.

Authors:  H G Pope; J O Cole; P T Choras; C E Fulwiler
Journal:  J Nerv Ment Dis       Date:  1986-08       Impact factor: 2.254

2.  Neuroleptic malignant syndrome associated with inappropriate antidiuresis and psychogenic polydipsia.

Authors:  C R Tomson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-18

3.  Managing an acutely manic 17-year-old girl with neuroleptic malignant syndrome.

Authors:  A Frances; V L Susman
Journal:  Hosp Community Psychiatry       Date:  1986-08

4.  Neuroleptic malignant syndrome: caffeine contracture of single muscle fibers and muscle pathology.

Authors:  M Araki; A Takagi; I Higuchi; H Sugita
Journal:  Neurology       Date:  1988-02       Impact factor: 9.910

5.  Neuroleptic malignant syndrome: successful treatment with bromocriptine.

Authors:  W M Verhoeven; A Elderson; H G Westenberg
Journal:  Biol Psychiatry       Date:  1985-06       Impact factor: 13.382

6.  Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome.

Authors:  M Ansseau; C F Reynolds; D J Kupfer; P F Poncelet; G Franck; A E Dresse; M Reznik
Journal:  J Clin Psychiatry       Date:  1986-06       Impact factor: 4.384

Review 7.  The neuroleptic malignant syndrome--a review.

Authors:  W R Gibb; A J Lees
Journal:  Q J Med       Date:  1985-08

8.  Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases.

Authors:  M Goulon; P de Rohan-Chabot; D Elkharrat; P Gajdos; C Bismuth; F Conso
Journal:  Neurology       Date:  1983-04       Impact factor: 9.910

9.  Neuroleptic malignant syndrome.

Authors:  M L Martin; E J Lucid; R W Walker
Journal:  Ann Emerg Med       Date:  1985-04       Impact factor: 5.721

10.  Neuroleptic malignant-like syndrome induced by metoclopramide.

Authors:  M R Samie
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.